Roche (RHHBY) is planning to move a new antibiotic into late stage clinical trials after early studies showed it had ...

Edward Owen, Therapeutic Area Director of Oncology and Early Clinical Development at Genentech, discussed clinical trials decarbonisation at CTO West Coast. Credit: Athanasios Psimadis/ Arena ...

A new antibiotic that has the potential to save millions of lives has entered its last phase of human testing. Swiss ...

A new study is the first phase 3 to show meaningful improvement in both progression-free and overall survival with first-line ...

The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body ...

New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients ...

Roche, hoping to carve out a standard-of-care spot for its PI3K inhibitor Itovebi, now has another leg to stand on with new ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) 100 mg/mL for the ...

The partnership will include $105m upfront to Orionis, with the potential for further payments that could exceed $2bn.

Roche (RHHBF) unit Genentech partners Orionis Biosciences to develop and commercialize cancer drugs in a deal that exceed $2B ...